Objective: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive, safe and efficacious technique for treating various neuropsychiatric disorders, but its underlying mechanisms are poorly understood. A newly developed H-coil allows the stimulation of deeper brain regions. This study is the first to investigate the effects of deep high-frequency rTMS on brain-derived neurotrophic factor (BDNF) serum concentrations in healthy volunteers. We aimed to evaluate the short-term effect of deep rTMS on BDNF serum concentrations. Methods: This was a double-blind, randomized deep high-frequency rTMS study using an H-coil on a cohort of 13 healthy volunteers (NCT01106365). The following stimulation protocols were applied: 18-Hz stimulation of the left dorsolateral prefrontal cortex (PFC), 5-Hz stimulation of the primary motor cortex (MC) and sham stimulation in random order. Blood samples were obtained before, 30 min after and 60 min after each treatment. Results: The BDNF serum concentration decreased significantly after MC and PFC stimulation, but not after sham stimulation. Furthermore, BDNF serum level changes were associated with changes in individual alertness. Conclusion: Although BDNF serum concentrations do not necessarily correlate with BDNF levels in the cerebrospinal fluid or the brain, these results indicate an acute biological effect of deep rTMS on BDNF release, and demonstrate that this change correlates with alertness.

Keywords:
Repetitive transcranial magnetic stimulation, Deep transcranial magnetic stimulation, High-frequency transcranial magnetic stimulation, Brain-Derived Neurotrophic Factor
1.
Rossi S, Hallett M, Rossini PM, Pascual-Leone A: Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009;120:2008-2039.
2.
McNamara B, Ray JL, Arthurs OJ, Boniface S: Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 2001;31:1141-1146.
3.
Rosenberg O, Shoenfeld N, Zangen A, Kotler M, Dannon PN: Deep TMS in a resistant major depressive disorder: a brief report. Depress Anxiety 2010;27:465-469.
4.
Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
5.
Croarkin PE, Wall CA, Lee J: Applications of transcranial magnetic stimulation (TMS) in child and adolescent psychiatry. Int Rev Psychiatry 2011;23:445-453.
6.
Russo-Neustadt AA, Chen MJ: Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 2005;11:1495-1510.
7.
Yukimasa T, Yoshimura R, Tamagawa A, Uozumi T, Shinkai K, Ueda N, et al: High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 2006;39:52-59.
8.
Zanardini R, Gazzoli A, Ventriglia M, Perez J, Bignotti S, Maria Rossini P, et al: Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 2006;91:83-86.
9.
Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002;109:143-148.
10.
Lang UE, Hellweg R, Gallinat J: BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004;29:795-798.
11.
Lee BH, Kim H, Park SH, Kim YK: Decreased plasma BDNF level in depressive patients. J Affect Disord 2007;101:239-244.
12.
Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, et al: Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005;51:234-238.
13.
Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, et al: Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 2007;68:512-517.
14.
Lang UE, Bajbouj M, Gallinat J, Hellweg R: Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation. Psychopharmacology 2006;187:56-59.
15.
Angelucci F, Oliviero A, Pilato F, Saturno E, Dileone M, Versace V, et al: Transcranial magnetic stimulation and BDNF plasma levels in amyotrophic lateral sclerosis. Neuroreport 2004;15:717-720.
16.
Lang UE, Hellweg R, Gallinat J, Bajbouj M: Acute prefrontal cortex transcranial magnetic stimulation in healthy volunteers: no effects on brain-derived neurotrophic factor (BDNF) concentrations in serum. J Affect Disord 2008;107:255-258.
17.
Schaller G, Sperling W, Richter-Schmidinger T, Mühle C, Heberlein A, Maihöfner C, et al: Serial repetitive transcranial magnetic stimulation (rTMS) decreases BDNF serum levels in healthy male volunteers. J Neural Transm 2014;121:307-313.
18.
Zangen A, Roth Y, Voller B, Hallett M: Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil. Clin Neurophysiol 2005;116:775-779.
19.
Weinges-Evers N, Brandt AU, Bock M, Pfueller CF, Dörr J, Bellmann-Strobl J, et al: Correlation of self-assessed fatigue and alertness in multiple sclerosis. Mult Scler 2010;16:1134-1140.
20.
Rossini PM, Barker AT, Berardelli A, Caramia MD, Caruso G, Cracco RQ, et al: Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994;91:79-92.
21.
Peinemann A, Reimer B, Löer C, Quartarone A, Münchau A, Conrad B, et al: Long-lasting increase in corticospinal excitability after 1,800 pulses of subthreshold 5-Hz repetitive TMS to the primary motor cortex. Clin Neurophysiol 2004;115:1519-1526.
22.
Quartarone A, Bagnato S, Rizzo V, Morgante F, Sant'Angelo A, Battaglia F, et al: Distinct changes in cortical and spinal excitability following high-frequency repetitive TMS to the human motor cortex. Exp Brain Res 2005;161:114-124.
23.
Hellweg R, Lohmann P, Huber R, Kühl A, Riepe MW: Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment. Learn Mem 2006;13:63-71.
24.
Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, et al: Serum neurotrophins: a study on the time course and influencing factors in a large old-age sample. Neurobiol Aging 2007;28:1436-1445.
25.
Hellweg R, Ziegenhorn A, Heuser I, Deuschle M: Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008;41:66-71.
26.
Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, et al: Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 2009;94:1062-1069.
27.
Cassiman D, Denef C, Desmet VJ, Roskams T: Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors. Hepatology 2001;33:148-158.
28.
Matthews VB, Aström MB, Chan MHS, Bruce CR, Krabbe KS, Prelovsek O, et al: Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 2009;52:1409-1418.
29.
Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, et al: Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 2000;127:4531-4540.
30.
Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002;328:261-264.
31.
Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al: Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14:347-353.
32.
Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, et al: Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009;42:270-276.
33.
Fitzgerald PB, Fountain S, Daskalakis ZJ: A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clin Neurophysiol 2006;117:2584-2596.
34.
Berardelli A, Inghilleri M, Rothwell JC, Romeo S, Currà A, Gilio F, et al: Facilitation of muscle evoked responses after repetitive cortical stimulation in man. Exp Brain Res 1998;122:79-84.
35.
Pascual-Leone A, Valls-Solé J, Wassermann EM, Hallett M: Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain 1994;117:847-858.
36.
Levkovitz Y, Harel EV, Roth Y, Braw Y, Most D, Katz LN, et al: Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimul 2009;2:188-200.
37.
Rosenberg O, Zangen A, Stryjer R, Kotler M, Dannon PN: Response to deep TMS in depressive patients with previous electroconvulsive treatment. Brain Stimul 2010;3:211-217.
38.
Isserles M, Rosenberg O, Dannon P, Levkovitz Y, Kotler M, Deutsch F, et al: Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. J Affect Disord 2011;128:235-242.
39.
Rosenberg O, Isserles M, Levkovitz Y, Kotler M, Zangen A, Dannon PN: Effectiveness of a second deep TMS in depression: a brief report. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1041-1044.
40.
Levkovitz Y, Sheer A, Harel EV, Katz LN, Most D, Zangen A, et al: Differential effects of deep TMS of the prefrontal cortex on apathy and depression. Brain Stimul 2011;4:266-274.
41.
Harel EV, Rabany L, Deutsch L, Bloch Y, Zangen A, Levkovitz Y: H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: an 18-week continuation safety and feasibility study. World J Biol Psychiatry 2012, Epub ahead of print.
42.
Roth Y, Amir A, Levkovitz Y, Zangen A: Three-dimensional distribution of the electric field induced in the brain by transcranial magnetic stimulation using figure 8 and deep H-coils. J Clin Neurophysiol 2007;24:31-38.
43.
Bilek E, Schäfer A, Ochs E, Esslinger C, Zangl M, Plichta MM, et al: Application of high-frequency repetitive transcranial magnetic stimulation to the DLPFC alters human prefrontal-hippocampal functional interaction. J Neurosci 2013;33:7050-7056.
44.
Groppa S, Muthuraman M, Otto B, Deuschl G, Siebner HR, Raethjen J: Subcortical substrates of TMS induced modulation of the cortico-cortical connectivity. Brain Stimul 2013;6:138-146.
45.
Siebner HR, Peller M, Bartenstein P, Willoch F, Rossmeier C, Schwaiger M, et al: Activation of frontal premotor areas during suprathreshold transcranial magnetic stimulation of the left primary sensorimotor cortex: a glucose metabolic PET study. Hum Brain Mapp 2001;12:157-167.
46.
Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature 2008;455:894-902.
47.
Groves JO: Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007;12:1079-1088.
48.
Ferris LT, Williams JS, Shen C-L: The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc 2007;39:728-734.
49.
Gersner R, Kravetz E, Feil J, Pell G, Zangen A: Long-term effects of repetitive transcranial magnetic stimulation on markers for neuroplasticity: differential outcomes in anesthetized and awake animals. J Neurosci 2011;31:7521-7526.
50.
Müller MB, Toschi N, Kresse AE, Post A, Keck ME: Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neurotrophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain. Neuropsychopharmacology 2000;23:205-215.
51.
Zhang X, Mei Y, Liu C, Yu S: Effect of transcranial magnetic stimulation on the expression of c-Fos and brain-derived neurotrophic factor of the cerebral cortex in rats with cerebral infarct. J Huazhong Univ Sci Technolog Med Sci 2007;27:415-418.
52.
Urbanek C, Weinges-Evers N, Bellmann-Strobl J, Bock M, Dörr J, Hahn E, et al: Attention Network Test reveals alerting network dysfunction in multiple sclerosis. Mult Scler 2010;16:93-99.
53.
Weinges-Evers N, Brandt AU, Bock M, Pfueller CF, Dörr J, Bellmann-Strobl J, et al: Correlation of self-assessed fatigue and alertness in multiple sclerosis. Mult Scler 2010;16:1134-1140.
54.
Döring A, Pfueller CF, Paul F, Dörr J: Exercise in multiple sclerosis: an integral component of disease management. EPMA J 2011;3:2.
55.
Veauthier C, Radbruch H, Gaede G, Pfueller CF, Dörr J, Bellmann-Strobl J, et al: Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler 2011;17:613-622.
56.
Finke C, Pech LM, Sömmer C, Schlichting J, Stricker S, Endres M, et al: Dynamics of saccade parameters in multiple sclerosis patients with fatigue. J Neurol 2012;259:2656-2663.
57.
Veauthier C, Paul F: Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist? Mult Scler 2012;18:248-249.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.